ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production
SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a company dedicated to improving quality of life through research and leadership in bio-pharmaceuticals and cannabinoid-based formulations, announced today that it has reached a positive milestone in the development of COVID-19 vaccine components by achieving plant-based expression, isolation, and purification of a potential antigen for a SARS-CoV-2 vaccine…
Details